Patients With Rectal Cancer: a "Wait-and-see" Approach

Recruiting N/A Interventional Study
Colorectal Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
48 (estimated)
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiotherapy to a dose of 45Gy in 25 fractions with a tumor boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary tumor), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse. Salvage onco…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pelvic MRI defined disease (at least one of the following): * mesorectum involved or breached - includes involvement of adjacent organ (s) (T3-T4) * involvement of muscularis propria (T2) * extra-mural vascular invasion * tumour deposit within the mesorectum * one o…
Contacts

Neil Kopek, M.D.

514-934-4440

neil.kopek@muhc.mcgill.ca

CONTACT

Marianna Perna, CCRP,CCRC

514-934-1934

marianna.perna@muhc.mcgill.ca

CONTACT